Lyra Therapeutics, Inc.
LYRA
$0.73
-$0.01-1.22%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 398.00K | 600.00K | 770.00K | 1.19M | 1.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 398.00K | 600.00K | 770.00K | 1.19M | 1.53M |
| Cost of Revenue | 1.01M | -22.01M | -20.16M | -12.00M | 1.36M |
| Gross Profit | -608.00K | 22.61M | 20.93M | 13.19M | 174.00K |
| SG&A Expenses | 11.54M | 12.61M | 14.31M | 15.95M | 18.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.95M | 33.01M | 36.56M | 46.35M | 62.27M |
| Operating Income | -29.55M | -32.41M | -35.79M | -45.17M | -60.73M |
| Income Before Tax | -28.91M | -32.93M | -38.82M | -79.50M | -93.40M |
| Income Tax Expenses | 11.00K | 15.00K | 19.00K | 29.00K | 39.00K |
| Earnings from Continuing Operations | -28.92 | -32.95 | -38.84 | -79.53 | -93.44 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.92M | -32.95M | -38.84M | -79.53M | -93.44M |
| EBIT | -29.55M | -32.41M | -35.79M | -45.17M | -60.73M |
| EBITDA | -29.09M | -31.90M | -35.34M | -44.70M | -60.26M |
| EPS Basic | -19.31 | -23.78 | -29.46 | -60.71 | -71.75 |
| Normalized Basic EPS | -11.85 | -13.93 | -16.13 | -20.51 | -27.82 |
| EPS Diluted | -19.31 | -23.78 | -29.46 | -60.71 | -71.75 |
| Normalized Diluted EPS | -11.85 | -13.93 | -16.13 | -20.51 | -27.82 |
| Average Basic Shares Outstanding | 6.21M | 5.74M | 5.28M | 5.24M | 5.21M |
| Average Diluted Shares Outstanding | 6.21M | 5.74M | 5.28M | 5.24M | 5.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |